Immatics N.V

NASDAQ:IMTX   4:00:00 PM EDT
5.38
-0.05 (-0.92%)
7:33:44 PM EDT: $5.36 -0.02 (-0.37%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)647.92M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$15.07 Million
Adjusted EPS-$0.35
See more estimates
10-Day MA$5.54
50-Day MA$5.22
200-Day MA$6.72
See more pivots

Immatics N.V Stock, NASDAQ:IMTX

Paul-Ehrlich-Strasse 19, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 343

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.